Antagonism of endogenous nociceptin/orphanin FQ inhibits infarction-associated ventricular arrhythmias via PKC-dependent mechanism in rats

Br J Pharmacol. 2013 Oct;170(3):614-23. doi: 10.1111/bph.12310.

Abstract

Background and purpose: Evidence indicates nociceptin/orphanin FQ (N/OFQ) may participate in the pathology of cardiac arrhythmias associated with myocardial infarction. But the role of N/OFQ in the arrhythmogenesis in acute myocardial infarction is unclear. The aim of this study was to investigate the effects of endogenous N/OFQ on infarction-associated arrhythmias.

Experimental approach: The expression of N/OFQ, PKC activity and ventricular arrhythmias in presence and absence of UFP-101, a specific antagonist of N/OFQ receptor, were examined following permanent coronary artery occlusion in anaesthetized rats. The effect of N/OFQ on action potential duration was examined in isolated rat cardiomyocytes.

Key results: It was observed that N/OFQ was increased by 41% in the myocardium after coronary artery occlusion (P < 0.01 vs. control). Pretreatment with UFP-101 (10(-7) mol·kg(-1) , i.v.) reduced the incidence of ventricular ectopic beats by 70% and ventricular tachycardia by 51% respectively (all P < 0.05 vs. control). Meanwhile, PKC activity was elevated in the rats treated with UFP-101 (by 35%, P < 0.05 vs. control). A selective PKC inhibitor, calphostin C, completely abolished the anti-arrhythmic effects of UFP-101 (P < 0.01). N/OFQ (at 10(-11) , 10(-9) and 1 × 10(-7) mol·L(-1) ) shortened the action potential duration by 3% (P > 0.05), 10% (P < 0.05) and 22% (P < 0.01), respectively, via N/OFQ receptor.

Conclusions and implications: Antagonism of endogenous N/OFQ produces anti-arrhythmic effects on ventricular arrhythmias in acute myocardial infarction, possibly via modulating PKC activity and action potential of myocytes.

Keywords: N/OFQ; PKC; action potential duration; acute myocardial infarction; nociceptin/orphanin FQ; ventricular arrhythmia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Animals
  • Anti-Arrhythmia Agents / pharmacology*
  • Disease Models, Animal
  • Male
  • Myocardial Infarction / complications
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / enzymology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Narcotic Antagonists*
  • Nociceptin Receptor
  • Opioid Peptides / pharmacology*
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism*
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid / metabolism
  • Signal Transduction / drug effects
  • Tachycardia, Ventricular / enzymology
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / prevention & control*
  • Time Factors
  • Ventricular Premature Complexes / enzymology
  • Ventricular Premature Complexes / etiology
  • Ventricular Premature Complexes / prevention & control*

Substances

  • (Nphe(1),Arg(14),Lys(15))N-OFQ NH(2)
  • Anti-Arrhythmia Agents
  • Narcotic Antagonists
  • Opioid Peptides
  • Protein Kinase Inhibitors
  • Receptors, Opioid
  • Protein Kinase C
  • Nociceptin Receptor
  • Oprl protein, rat